Eric P. Seest
Eli Lilly (United States)(US)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, HIV Research and Treatment, Analytical Chemistry and Chromatography, Chemical Synthesis and Analysis, Cyclopropane Reaction Mechanisms
Most-Cited Works
- → Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class(1998)295 cited
- → Structure-Based Design of HIV Protease Inhibitors: Sulfonamide-Containing 5,6-Dihydro-4-hydroxy-2-pyrones as Non-Peptidic Inhibitors(1996)96 cited
- → Design, synthesis, structure–activity relationship, and in vivo activity of azabicyclic aryl amides as α7 nicotinic acetylcholine receptor agonists(2006)94 cited
- → Synthesis and Evaluation of11C-LY2795050 as a κ-Opioid Receptor Antagonist Radiotracer for PET Imaging(2013)91 cited
- → Identification of Phenylisoxazolines as Novel and Viable Antibacterial Agents Active against Gram-Positive Pathogens(2002)89 cited
- → Discovery and Characterization of QPT-1, the Progenitor of a New Class of Bacterial Topoisomerase Inhibitors(2008)87 cited
- → Structure-Based Design of Nonpeptidic HIV Protease Inhibitors: The Sulfonamide-Substituted Cyclooctylpyranones(1997)85 cited
- → Stereoselective Synthesis of Furo[2,3-c]pyridine Pyrimidine Thioethers, A New Class of Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors(1998)63 cited
- → (−)-6-Chloro-2-[(1-furo[2,3-c]pyridin-5-ylethyl)thio]-4-pyrimidinamine, PNU-142721, a New Broad Spectrum HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor(1998)48 cited
- → Screening strategies for achiral supercritical fluid chromatography employing hydrophilic interaction liquid chromatography-like parameters(2012)43 cited